First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial

  1. Albiges, L.
  2. Tannir, N.M.
  3. Burotto, M.
  4. McDermott, D.
  5. Plimack, E.R.
  6. Barthélémy, P.
  7. Porta, C.
  8. Powles, T.
  9. Donskov, F.
  10. George, S.
  11. Kollmannsberger, C.K.
  12. Gurney, H.
  13. Grimm, M.-O.
  14. Tomita, Y.
  15. Castellano, D.
  16. Rini, B.I.
  17. Choueiri, T.K.
  18. Leung, D.
  19. Saggi, S.S.
  20. Lee, C.-W.
  21. McHenry, M.B.
  22. Motzer, R.J.
Revista:
European Urology

ISSN: 1873-7560,  0302-2838

Any de publicació: 2022

Volum: 81

Número: 3

Pàgines: 266-271

Tipus: Article

DOI: 10.1016/J.EURURO.2021.10.001 GOOGLE SCHOLAR lock_openAccés obert editor
Font de les dades: Scopus